Company Dossier · Health Care
Solventum
- S&P 500
- Russell 1000
What Solventum is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $8.31 billion, down 1.0% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: −$0.12 billion.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.33 billion, down 25% from a year earlier.SEC EDGAR filings (XBRL)
- Latest earnings call or results release (August 5, 2026): sentiment 0.30 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 27, 2026): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q1 2026: $0.1 million on the open market.SEC Form 4
- 886 institutional managers reported a position at June 30, 2026 (+1 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 12 (7 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Solventum is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending7th pct
- Debt raised45th pct
- Buybacks vs capex—
- Hiring filings76th pct
- Deals and private raises40th pct
- Patent publications87th pct
Confident ↔ Hedging
Mixed
- Call sentiment17th pct
- Call confidence55th pct
- Guidance changes71st pct
- Risk factors added22nd pct
- Insider open-market trades—
- − Call sentiment
- + Guidance changes
- − Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver13th pct
- Stress filings48th pct
Credit
How these are built →Solventum's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$5.3B
- Due within a year $0.5B
- Longer term $4.8B
- Default point $2.9B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC))third_quarter 2026 · $0.1 million
- Oct 21, 2026LobbyingLobbying report (SOLVENTUM CORPORATION)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MONUMENT ADVOCACY)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 19, 2026LobbyingLobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
- Jul 21, 2026LobbyingLobbying report (SOLVENTUM CORPORATION)second_quarter 2026 · $0.2 million
- Jul 20, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC))second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (MONUMENT ADVOCACY)second_quarter 2026 · $0.1 million
- Jul 18, 2026LobbyingLobbying report (TIBER CREEK GROUP)second_quarter 2026 · $0.1 million
- May 27, 20268-KDirector or officer changeItem 5.02
- May 20, 20268-KShareholder vote resultsItem 5.07
- Mar 24, 20268-KDirector or officer changeItem 5.02
- Feb 27, 202610-KAnnual report (10-K)3 risk factors added, 0 removed
- Oct 21, 20258-KDirector or officer changeItem 5.02
- Sep 2, 20258-KAcquisition or sale completedItem 2.01
- Jun 25, 20258-KMaterial agreement signedItem 1.01
- May 2, 20258-KShareholder vote resultsItem 5.07
- Mar 14, 2025Risk event
- Feb 28, 202510-K
- Feb 27, 20258-KMaterial agreement signedItem 1.01
- Nov 5, 20248-KDirector or officer changeItem 5.02
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Veeva Systems VEEV | $3.5B | — | Jul 31, 2026 |
| Zimmer Biomet ZBH | $8.5B | $1.5B | Jun 30, 2026 |
| Agilent Technologies A | $7.4B | $1.3B | Jul 31, 2026 |
| Zoetis ZTS | $9.5B | $2.3B | Jun 30, 2026 |
| Biogen BIIB | $9.9B | $2.4B | Mar 31, 2026 |
| Avantor AVTR | $6.5B | $0.4B | Mar 31, 2026 |
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
Identity
- SEC CIK
- 1964738
- Wikidata
- Q124795355
- SAM UEI
- NYZ3A8USQ3X9
- SAM UEI
- T3CSHMRPTGT2